PubMed · 16874948
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Anna Falanga. 2004. Thrombotic problems in hematologic malignancies.. https://pubmed.ncbi.nlm.nih.gov/16874948/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Allogeneic hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning has been extensively evaluated in patients with hematologic malignancies who are ineligible for conventional HCT because of age or medical comorbidities. Nonmyeloablative regimens have led to an initial state of mixed hematopoietic chimerism defined as coexistence of donor- and host-derived hematopoiesis. While nonmyeloablative regimens have been associated with reduced regimen-related toxicities in comparison with conventional myeloablative conditioning, graft rejection, graft-versus-host disease (GVHD), and disease progression have remained significant challenges. In this article, after briefly introducing current techniques for chimerism assessment, we describe factors affecting donor chimerism levels after nonmyeloablative conditioning, and then review data suggesting that chimerism assessment early after HCT might help identify patients at risk for graft rejection, GVHD and relapse/progression. Finally, we discuss how these observations have opened the way to further research protocols evaluating manipulation of postgrafting immunosuppression, and/or infusion of donor immune cells.
The cAMP signalling pathway has emerged as a key regulator of haematopoietic cell proliferation, differentiation and apoptosis. In parallel, general understanding of the biology of cyclic nucleotide PDEs (phosphodiesterases) has advanced considerably, revealing the remarkable complexity of this enzyme system that regulates the amplitude, kinetics and location of intracellular cAMP-mediated signalling. The development of therapeutic inhibitors of specific PDE gene families has resulted in a growing appreciation of the potential therapeutic application of PDE inhibitors to the treatment of immune-mediated illnesses and haematopoietic malignancies. This review summarizes the expression and function of PDEs in normal haematopoietic cells and the evidence that family-specific inhibitors will be therapeutically useful in myeloid and lymphoid malignancies.
This editorial describes the changes to Hematological Oncology over the past 12 months and redefines the scope and the goals of the journal. As well as changes in format, an electronic manuscript submission system and a stringent peer-review policy (outlined here) have been implemented. The journal is a vehicle for high-quality articles in the broad field of experimental and clinical hematological oncology, and a medium for the publication of translational research. As well as submitted material, the journal solicits and publishes high-quality reviews from leading experts.